NBY - NovaBay Pharmaceuticals, Inc.
NYSE
->
Healthcare
->
Biotechnology
EmeryVille,
United States
Type: Equity
NBY price evolution
NBY
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.7 | $0.55 | $0.73 | $0.76 |
| Inventory | $0.47 | $0.7 | $0.66 | $2.88 |
| Total current assets | $2.28 | $2.25 | $3.59 | $7.15 |
| Long term investments | ||||
| Property, plant & equipment | $1.1 | $1.2 | $1.29 | $1.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $3.88 | $3.92 | $5.36 | $9.03 |
| Current liabilities | ||||
| Accounts payable | $0.4 | $1.24 | $1.12 | $1.13 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.98 | $3.61 | $3.92 | $4.28 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.81 | $4.54 | $5.2 | $5.72 |
| Shareholders' equity | ||||
| Retained earnings | -$182.25 | -$180.03 | -$178.44 | -$174.85 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.95 | |||
| Short term investments | ||||
| Net receivables | $0.76 | $1.97 | $1.67 | $1.11 |
| Inventory | $2.88 | $3.44 | $3.22 | $0.61 |
| Total current assets | $7.15 | $11.33 | $13.17 | $14.24 |
| Long term investments | ||||
| Property, plant & equipment | $1.38 | $1.95 | $0.6 | $0.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1 | |||
| Total investments | ||||
| Total assets | $9.03 | $16.4 | $23.98 | $15.24 |
| Current liabilities | ||||
| Accounts payable | $1.13 | $1.08 | $1.04 | $0.3 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.28 | $4.26 | $3.44 | $2.83 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.09 | |||
| Total debt | ||||
| Total liabilities | $5.72 | $5.84 | $13.81 | $2.92 |
| Shareholders' equity | ||||
| Retained earnings | -$174.85 | -$158.15 | -$141.89 | -$136.06 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.44 | $2.4 | $2.63 | $3.73 |
| Cost of revenue | ||||
| Gross Profit | $1.59 | $1.59 | $1.79 | $1.81 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2.65 | $2.64 | $3.37 | $2.61 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.16 | $0.26 | $0.05 | |
| Net income | ||||
| Net income | -$2.22 | -$1.58 | -$3.59 | -$9.17 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14.73 | $14.4 | $9.93 | |
| Cost of revenue | ||||
| Gross Profit | $7.89 | $7.78 | $5.96 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $12.9 | $15.46 | $13.36 | |
| Operating income | -$6.43 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.01 | |||
| Interest expense | $0.02 | $4.09 | ||
| Net income | ||||
| Net income | -$16.7 | -$16.27 | -$11.03 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $1.06 | $1.07 | $1.07 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.79 | -$1.29 | -$0.8 | $1.91 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.35 | -$2.38 | -$1.31 | -$2.24 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$11.04 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$4.72 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$0.11 | -$12.04 | -$0.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.91 | $4.63 | $16.79 | $9.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.24 | -$2.13 | -$4.44 | $5.01 |
News
Fundamentals
| Market cap | $6.16M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 4.88M |
| Revenue | $11.20M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$16.57M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.37 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.55 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.39 |
|---|---|
| ROA | -298.56% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.15 |
| Quick ratio | 0.91 |